A Single-arm, Open-label, Multicenter, Phase II Study of BAY88-8223 in the Treatment of Japanese Patients With Symptomatic Castration-resistant Prostate Cancer (CRPC) With Bone Metastases
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Adenocarcinoma; Bone metastases; Prostate cancer
- Focus Therapeutic Use
- Sponsors Bayer
- 08 Jun 2017 Status changed from active, no longer recruiting to completed.
- 30 Nov 2016 Planned primary completion date changed from 1 Nov 2014 to 1 May 2017.
- 04 Jan 2016 Results will be presented at the 2016 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU), according to a Bayer media release.